Skip to main content
Premium Trial:

Request an Annual Quote

Kirk Malloy

NanoString Technologies has appointed Kirk Malloy to its Board of Directors. Malloy brings 20 years of experience in the life science tools, applied markets, and molecular diagnostics markets. He is the founder of consulting firm BioAdvisors, and was previously senior VP and general manager of life sciences and applied markets at Illumina. Prior to that, Malloy worked at Biosite and Qiagen. He also sits on the boards of publicly traded Organovo Holdings and the privately-held firms Edico Genome, iGenomx, and Agilome. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.